Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer%26apos;s Disease: The Role of APP

作者：Doran Eric; Keator David; Head Elizabeth; Phelan Michael J; Kim Ron; Totoiu Minodora; Barrio Jorge R; Small Gary W; Potkin Steven G; Lott Ira T

来源：Journal of Alzheimer's Disease, 2017, 56(2): 459-470.

DOI：10.3233/JAD-160836

• Alzheimer's disease
• amyloid-beta
• amyloid beta-protein precursor
• APP
• dementia
• down syndrome
• partial trisomy 21
• PiB-PET
• trisomy 21

Overexpression of the amyloid precursor protein (APP) gene on chromosome 21 in Down syndrome (DS) has been linked to increased brain amyloid levels and early-onset Alzheimer's disease (AD). An elderly man with phenotypic DS and partial trisomy of chromosome 21 (PT21) lacked triplication of APP affording an opportunity to study the role of this gene in the pathogenesis of dementia. Multidisciplinary studies between ages 66-72 years comprised neuropsychological testing, independent neurological exams, amyloid PET imaging with C-11-Pittsburgh compound-B (PiB), plasma amyloid-beta(A beta) measurements, and a brain autopsy examination. The clinical phenotype was typical for DS and his intellectual disability was mild in severity. His serial neuropsychological test scores showed less than a 3% decline as compared to high functioning individuals with DS who developed dementia wherein the scores declined 17-28% per year. No dementia was detected on neurological examinations. On PiB-PET scans, the patient with PT21 had lower PiB standard uptake values than controls with typical DS or sporadic AD. Plasma A beta(42) was lower than values for demented or non-demented adults with DS. Neuropathological findings showed only a single neuritic plaque and neurofibrillary degeneration consistent with normal aging but not AD. Taken together the findings in this rare patient with PT21 confirm the obligatory role of APP in the clinical, biochemical, and neuropathological findings of AD in DS.

• 出版日期2017